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This study evaluated the pharmacokinetics of topical creams containing 15% paromomycin (“paromomycin alone”) and 15%
paromomycin plus 0.5% gentamicin (WR 279,396) in patients with cutaneous leishmaniasis. The investigational creams were
applied topically to all lesions once daily for 20 days. Plasma samples were analyzed for simultaneous quantitation of paromo-
mycin and gentamicin isomers and total gentamicin. Pharmacokinetic parameters for gentamicin could not be calculated be-
cause detectable levels were rarely evident. After one application, the paromomycin area under the concentration-time curve
from 0 to 24 h (AUC0 –24) was 2,180 2,621 ng · h/ml (mean standard deviation [SD]) for the paromomycin-alone group and
975.6 1,078 ng · h/ml for the WR 279,396 group. After 20 days of application, the paromomycin AUC0 –24 and maximum con-
centration of drug (Cmax) were 5 to 6 times greater than those on day 1 for both treatment groups. For the paromomycin-alone
group, the AUC0 –24 was 8,575 7,268 ng · h/ml and the Cmax was 1,000 750 ng/ml, compared with 6,037 3,956 ng · h/ml and
660 486 ng/ml for the WR 279,396 group, respectively. Possibly due to large intersubject variability, no differences (P> 0.05)
in the AUC0 –24 or Cmax were noted between treatment or between sites on day 1 or 20. The percentage of dose absorbed on day 20
was 12.0% 6.26% and 9.68% 6.05% for paromomycin alone and WR 279,396, respectively. Paromomycin concentrations in
plasma after 20 days of application were 5 to 9% of those after intramuscular administration of 15 mg/kg of body weight/day to
adults for the systemic treatment of visceral leishmaniasis. Effective topical treatment of cutaneous leishmaniasis appears to be
possible with limited paromomycin and gentamicin systemic absorption, thus avoiding drug accumulation and toxicity. (The
work described here has been registered at ClinicalTrials.gov under registration no. NCT01032382 and NCT01083576.)
Acombination of paromomycin and gentamicin in a topicalcream formulation (WR279,396) is being investigated for the
treatment of uncomplicated cutaneous leishmaniasis (CL), a par-
asitic infection caused by the bite of a sandfly that results in an
ulcerated skin lesion frequently 2 to 5 cm in diameter (1). Leish-
maniasis has been found inmore than 90 countries worldwide (2).
It is estimated that the incidence of CL ranges from 0.7 million to
1.2 million cases annually (2). In the United States, CL has been
found in southern Texas along the Mexican border (3) and in
travelers returning from areas of endemicity (4). In the U.S. mil-
itary, more than 3,100 cases of CL have been parasitologically
confirmed since April 2003 at the Leishmania Diagnostics Labo-
ratory at the Walter Reed Army Institute of Research. Although
CL ultimately self-cures, the infection can create substantial mor-
bidity due to the continued presence of a skin ulcer and the psy-
chological impact of disfigurement (5).
Currently, there are no FDA-approved drugs for the treatment
of any form of CL in the United States. Several topical agents have
been investigated to treat CL, and at least one is available commer-
cially outside the United States. The primary active drug in these
topical formulations is paromomycin, an aminoglycoside antibiotic
that has a structure analogous to that of the antibacterial agent neo-
mycin. A new formulation (WR 279,396) additionally contains gen-
tamicin, which has been shown in animalmodels of CL to potentiate
the efficacy of the paromomycin-based topical cream formulation
(6).
In clinical trials, WR 279,396 is administered once a day for 20
days for the treatment of CL. Because WR 279,396 is a combina-
tion drug, the efficacy of the combination product compared with
that of the individual aminoglycosides is a mandatory part of the
clinical development. Since only the paromomycin component
has direct antiparasitic activity against Leishmania (7) and genta-
micin is postulated to act indirectly via immunomodulation (8–
10) and reduction of secondary bacterial infections in ulcerated
skin lesions (11), the paromomycin-gentamicin cream (WR
279,396) is being compared to an identical formulation called
“paromomycin alone,” which does not contain 0.5% gentamicin.
A recent study demonstrated that both paromomycin-gentamicin
(WR 279,396) and paromomycin-alone creams yielded similar
cure rates for ulcerative CL, with rates of 81% and 82%, respec-
tively, compared to rates of 58% for vehicle control (11). As part of
the safety profile of this combination topical drug, the determina-
tion of the amount of the dose absorbed is important. Thus, the
pharmacokinetics (PK) of both the WR 279,396 and paromomy-
cin-alone formulations were investigated in the context of two
phase 2 clinical trials, one in Peru and the other in Panama (reg-
istered at ClinicalTrials.gov under registration no. NCT01032382
andNCT01083576), and are the subject of this report. In addition,
although the PK and safety of parenteral formulations of paromo-
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mycin and gentamicin separately are well known, it is not known
to what extent these two drugs will be absorbed into the systemic
circulation when applied topically in the investigational product
formulation to an open skinwound, such as aCL lesion. The safety
and efficacy of these two topical formulations are the subjects of
other publications (11, 12).
MATERIALS AND METHODS
Study design. The study was a two-site (Lima, Peru, and Panama City,
Panama), randomized, double-blind, two-group trial assessing the PK,
safety, and efficacy of WR 279,396 and paromomycin-alone creams in 60
subjects with uncomplicated CL. At each site, subjects were randomized
in a targeted 1:1 ratio to receive either WR 279,396 (each gram of cream
contains 150 mg [15% {wt/wt}] paromomycin USP base and 5 mg [0.5%
{wt/wt}] gentamicin USP base) (target n  15) or paromomycin alone
(each gram of cream contains 150 mg [15% {wt/wt}] paromomycin USP
base) (target n 15) by topical application to CL lesions once daily for 20
days. Since it was desired to determine PK in different age groups, subjects
were stratified by age: 5 to 17 years and18 years, with no more than 18
total subjects per site randomized in any age range. The weight of the tube
containing the investigational cream was measured each day after treat-
ment, with a baseline weight taken at the beginning of treatment to esti-
mate total exposure to the drug.
In adult subjects, on days 1 and 20, bloodwas collected prior to topical
cream application and at 0.5 h, 1 h, 2 h, 3 h, and 4 h 5min and at 8 h, 12
h, and 24 h 15 min after completion of cream application to determine
plasma levels of paromomycin and gentamicin to calculate PK parame-
ters. Thus, the last blood draw in this series occurred on day 21. In addi-
tion, bloodwas collected ondays 4, 7, 12, and 17 1 day before study drug
application to examine trough plasma levels of paromomycin and genta-
micin. A follow-up plasma sample for PK analysis was obtained from
adults on day 28 2 days.
Subjects under the age of 18 years had a total of four blood samples
drawn (pre- and 4 h postapplication on study days 1 and 20).
Ethics. The study was sponsored by the Office of the SurgeonGeneral,
Department of theArmy,United States, andwas conducted in accordance
with the Belmont Principles and with all applicable laws, rules, and regu-
lations of the United States, Peru, and Panama. The investigators adhered
to the policies for protection of human subjects as prescribed in U.S.
Department of Defense Instruction 3216.02, U.S. Army Regulations 70-
25, and 40-7, and U.S. Food and Drug Administration regulations.
In Peru, the protocol was approved by the Independent Ethics Com-
mittee (IEC) of the Universidad Peruana Cayetano Heredia (UPCH) and
the IEC of Hospital Nacional Cayetano Heredia (HNCH) in Lima City.
The Ministry of Health of Peru approved importation of the study drug.
In Panama, the protocolwas approved by the PanamanianNational Com-
mittee of Bioethics for Research, Panama City, Panama. In the United
States, the protocol was approved by the Human Research Protections
Office, U.S. ArmyMedical Research andMateriel Command, Ft. Detrick,
MD. Written informed consent was obtained from all adult patients and
from the legal representatives of all minors. In addition, all minors pro-
vided witnessed assent.
Measurement of plasma concentrations of paromomycin and gen-
tamicin. Blood (approximately 3 ml) was collected via an intravenous
catheter or by venipuncture in K2 EDTA Vacutainer tubes for paromo-
mycin and gentamicin plasma concentration determination at various
time points during the study. Blood tubes were centrifuged at 3,000 rpm
for 10min at approximately 4°C, and the plasmawas separated and stored
at 65°C until shipping to the Drug Studies Unit of the University of
California at San Francisco for bioanalysis. Human plasma samples (0.2
ml) were analyzed for gentamicin and paromomycin with a liquid chro-
matography-tandemmass spectrometry (LC-MS/MS) procedure in aMi-
cromass Quattro LC Ultima system equipped with an Allure PFP propyl
column (4.6 by 50 mm, 5-m particle size), a mobile-phase system con-
sisting of methanol-water-trifluoroacetic acid (45:55:0.06 [vol/vol]) with
5 mM ammonium acetate and 3.0 mg ammonium phosphate dibasic per
liter. Mass spectrometric detection was performed with positive ioniza-
tion by (electrospray ionization (ESI) and mass scanning by multiple re-
action monitoring (MRM) analysis. The LC-MS/MS method was vali-
dated for simultaneous quantitation of paromomycin and isomers of
gentamicin (C1, C1a, and C2), as well as total gentamicin in plasma samples.
The lower limitsofquantitation(LLOQ)were13.20ng/ml forgentamicinC1,
12.25 ng/ml for gentamicin C1a, 21.25 ng/ml for gentamicin C2, and 50.0
ng/ml for gentamicin (total) and paromomycin. Interday assay precision
ranged from a 2.77% coefficient of variation (CV) to a 4.19% CV for total
gentamicin and a 2.87%CV to 3.72%CV for paromomycin.
PK analysis. Scheduled sampling times were used in all PK parameter
calculations and plots for paromomycin and gentamicin. Noncompart-
mental PK parameters based on the area under the concentration-time
curve (AUC) and the terminal-phase exponential rate constant (z) were
estimated with a validated PK software program,WinNonLin 5.3 (Pharsight
Corp.,MountainView,CA).The linear trapezoidal rulewas applied toobtain
AUC estimates. If plasma concentrations fell to zero, these values were also
included in calculating theAUC from0 to 24 h (AUC0–24) by the trapezoidal
rule. The zwas calculated as the negative slope of the regression line for the
terminal linear portion of the natural logarithm (ln)-transformed plasma
concentration-versus-time curve. Selectionof terminal timepointswasmade
based on the software and review of selected points. Estimates of paromomy-
cin half-life (t1/2) that were longer than the time interval utilized to estimate
the t1/2 were excluded from the PK and summary tables.
Parameters were calculated for paromomycin following topical appli-
cation in adults on day 1 and day 20. No PK analysis was performed based
upon gentamicin plasma concentrations, since nearly all gentamicin plasma
concentrations were below quantifiable limits. As described above, z was
reported when z could be estimated, and t1/2 was determined as ln(2)/z.
Values of AUC0–24, maximum concentration of drug (Cmax), and time to
maximum concentration of drug (Tmax) for paromomycin were estimated
over the 24-hperiod after dosing. Since the applieddoses of the creamsvaried
among subjects, values of AUC0–24 divided by the topical creamdose for that
period (AUC/D) andCmax divided by topical creamdose (Cmax/D) were also
calculated.Drug concentrations in plasma for children in the table and adults
in graphs were normalized for the average overall cream dose of 2.81 g.
The percentage of paromomycin absorbed systemically following top-
ical administration (% dose) was determined from the AUC0–24 and a
mean total body clearance value from the literature by Kanyok et al., 1997
(13), as follows: % dose  AUC0–24  (paromomycin clearance of 7.32
liters/h/1.73 m2) 100/(topical drug dose during that interval).
The total body clearance value was the mean of the two reported esti-
mates for 12-mg/kg-of-body-weight- and 15-mg/kg single-intramuscular
(i.m.)-paromomycin-dose groups (13). This calculation is correct under
steady-state conditions. Thus, the % dose on day 1 was not reported.
Estimates of%dose on day 20 assume steady-state conditionswith similar
doses during the steady-state period.
Statistical analysis. To assess the influence of treatment (paromomy-
cin a1lone or WR 279,396) and clinical site on the paromomycin PK,
paromomycin concentrations in plasma and PK parameters were com-
pared. Comparisons between plasma drug concentrations at each collection
period between sites and treatmentswere performedby a one-way analysis of
variance (ANOVA) (WinNonLin5.3, PharsightCorp.,MountainView,CA).
ParomomycinPKestimateswerecomparedwithrespect to treatmentandsite
by a one-way ANOVA utilizing ln-transformed parameters.
Ordinary least-squares regression was used to examine the relation-
ships between treatment, subject. and lesion characteristics (clinical site,
age, gender, weight, body surface area [BSA], creatinine clearance, treat-
ment prescribed, cumulative dose, and lesion area) and PK outcomes
(Cmax,Tmax, AUC,Cmax/dose, and AUC/dose). Each of the characteristics
was analyzed independently in a single-variable model with each PK out-
come. Factors that displayed some evidence of association, defined by a P
value of 0.25 or less, were included in a multivariate regression model for
that PK outcome.
Ravis et al.
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RESULTS
Subjects. At the Peru site, 5 adult subjects received paromomycin
alone and 4 adult subjects were treated with WR 279,396 for 20
days. For thePanama site, 8 adult subjectswere treatedwithparomo-
mycin-alone cream and 9 adult subjects receivedWR 279,396 for 20
days. For children, 18 children received paromomycin alone in Peru
(n 11) and Panama (n 7), while 16 children were administered
WR 279,396 in Peru (n 10) and Panama (n 6).
Demographics. The demographics for the adult and child
populations are shown in Table 1. Within the two age groups,
there were no differences in age, weight, lesion size, body surface
area (BSA), or creatinine clearance (CrCl) (Cockcroft and Gault
[14]) between treatments or between sites.
Gentamicin PK evaluation. No measurable gentamicin con-
centrations in plasma were noted in adult or child subjects receiv-
ing paromomycin-alone cream, which does not contain gentami-
cin.Only at a few times throughout the studywithWR279,396 did
the gentamicin plasma concentrations exceed the LLOQ (13.20
ng/ml for gentamicin C1, 12.25 ng/ml for gentamicin C1a, 21.25
ng/ml for gentamicinC2, and50.0ng/ml for total gentamicin).These
measurable gentamicin concentrations in plasma occurred 9 times
on day 20 and once on day 1 (data not shown). No trendwith regard
to site or age group (5 adults and 5 children) was noted.
Paromomycin PK analysis. A semilog plot of mean  stan-
dard deviation (SD) observed paromomycin plasma concentra-
tions standard deviation (SD) at the scheduled collection times
is presented in Fig. 1 (day 1) and 2 (day 20). During day 1, three
subjects in the paromomycin-alone group and 4 subjects in the
WR279,396 group had nomeasurable paromomycin plasma con-
centrations. Summary statistics for paromomycin PK analysis in
adults on day 1 and day 20 are shown in Table 2. Estimates of z
were calculated when there were sufficient concentrations to de-
termine a slope and were reported only if the paromomycin t1/2
was longer than the time interval utilized to estimate the t1/2 (2
profiles on day 20).
A comparison of paromomycin concentrations in plasma by
collection time showed no effect of treatment (WR 279,396 versus
paromomycin alone) at any time period for both the day 1 and day
20 concentration profiles. Within each treatment group and day,
no influence of study site (Peru versus Panama) was noted on
observed paromomycin plasma concentrations except at two
times. These times were day 20 for both adult treatment groups at
8 h and in theWR 279,396 treatment group on days 17 and 20 for
adults. It must be recognized that between-site comparisons in-
volved small numbers of subjects, with only four subjects in some
Peru treatment groups.
On day 20, paromomycin AUC0-24 and Cmax estimates were
greater (P  0.05) than those noted on day 1 for both treatment
groups. There were no significant differences (P  0.05) in
AUC0-24 or Cmax between treatment groups or sites, and this was
also true for the dose-adjusted AUC/D and Cmax/D estimates.
Paromomycin plasma concentrations in children. Table 3
presents a summary of paromomycin plasma concentrations in 34
children following topical administration of both creams. One
FIG 1 Semilog plots of paromomycin plasma concentration means SD as a
function of time following administration of paromomycin-alone (Œ) or WR
279,396 () cream on day 1 in adult subjects. Plasma concentrations are nor-
malized to the average cream dose.
FIG 2 Linear and semilog plots of paromomycin plasma concentration
means SD as a function of time following administration of paromomycin-
alone (Œ) or WR 279,396 () cream on day 20 in adult subjects. Plasma
concentrations are normalized to the average cream dose.
TABLE 1 Adult and child demographic characteristics and dose exposure
Group Treatment
No. of
subjects
Value for treatment groupc
Age, yrs
Sex,
M/Fa Wt, kg
Lesion
size,b mm2 BSA, m2
CrCl,
ml/min Total dose, g
Adult Paromomycin 13 37 (14) 10/3 74 (19) 332 (317) 1.83 (0.30) 110.7 (28.5) 53.3 (21.4)
WR 279,396 13 36 (12) 8/5 77 (15) 175 (163) 1.88 (0.23) 121.1 (44.5) 57.8 (25.3)
Child Paromomycin 18 11.4 (4.1) 14/4 40.6 (17.6) 155 (158) 1.25 (0.37) 101.0 (28.4) 58.0 (20.0)
WR 279,396 16 10.3 (2.9) 13/3 35.8 (12.7) 112 (175) 1.16 (0.29) 101.7 (30.1) 45.0 (13.9)
a M, male; F, female.
b At baseline.
c Values are means (SD) except for sex of subjects.
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child displayed extremely high plasma paromomycin concentra-
tions on the first dose, with 0- and 4-h concentrations of 221 and
2,460 ng/ml. In contrast, this subject did not have detectable
plasma concentrations at day 20, when it would be expected.
Therefore, it is possible that these samples weremislabeled. Drop-
ping the data for subject 313 resulted in mean paromomycin
plasma concentrations of 0 and 90.5 ng/ml at these times on day 1
in children, respectively.
There was no significant difference (P 0.05) in paromomy-
cin plasma concentrations between paromomycin-alone- or WR
279,396-treated children at any of the times compared on day 1 or
day 20. For both treatments, plasma concentrations on day 20
appeared higher at both 0- and 4-h collection times than those on
day 1. Paromomycin Cmax plasma concentrations by age group
were not significantly different (P 0.05) on day 1 or 20.
Percentage of paromomycin dose systemically absorbed and
accumulation. Utilizing day 20 paromomycin PK parameters, es-
timates of the percentages of systemic absorption following topi-
TABLE 2 Paromomycin PK following administration of paromomycin alone or WR 279,396 to adults on day 1 and day 20
Day, treatment, and statistica Dose (g) CumDoseb (g)
Cmax
(ng/ml) Tmax (h)
AUC0–24
(ng · h/ml) t1/2 (h)
Cmax/D
c
(1/ML)
AUC/Dd
(h/ML)
Day 1
Paromomycin
No. of subjects 13 13 13 10 13 9 13 13
Mean value (% CV) 2.1 (69.8) 2.1 (69.8) 331 (112.2) 2.50 (38.9) 2,180 (120.2) 5.04 (118.4) 135 (90.7) 823.5 (99.0)
GeoMean value 1.7 1.7 79.1 2.32 278.7 3.50 44.3 156.0
WR 279,396
No. of subjects 13 13 13 9 13 6 13 13
Mean value (% CV) 2.6 (54.7) 2.6 (54.7) 131 (85.7) 2.89 (76.3) 975.6 (110.5) 4.15 (35.2) 56.6 (98.5) 344.3 (89.8)
GeoMean value 2.3 2.3 35.6 2.33 125.7 3.96 18.6 65.69
P value
Day 1 ANOVA, site 0.472 0.245 0.585 0.611 0.704
Day 1 ANOVA, treatment 0.478 0.841 0.597 0.353 0.500
Day 20
Paromomycin
No. of subjects 13 13 13 13 13 11 13 13
Mean value (% CV) 3.4 (50.4) 53.3 (40.1) 1,000 (74.8) 3.12 (73.0) 8,575 (84.8) 5.96 (43.5) 281 (51.5) 2,344 (53.3)
GeoMean value 3.0 48.6 751 2.52 6,173 5.53 252 2,070
WR 279,396
No. of subjects 13 13 13 12 13 12 13 13
Mean value (% CV) 3.4 (55.4) 57.8 (43.7) 660 (73.7) 2.46 (53.1) 6,037 (65.5) 6.94 (47.6) 211 (61.5) 1,926 (76.1)
GeoMean value 2.8 52.1 354 2.07 2,681 6.21 135 1,022
P value for day 20
ANOVA, site 0.208 0.103 0.490 0.097 0.166 0.136
ANOVA, treatment 0.645 0.235 0.533 0.310 0.209 0.299
P value for day 20 vs day 1, ANOVA 0.082 0.003 0.012 0.005 0.004 0.007
a GeoMean, geometric mean.
b Cumulative dose.
c Cmax/D, Cmax divided by administered dose of cream. ML, megaliter.
d AUC/D, AUC0–24 divided by administered dose of cream.
TABLE 3 Paromomycin concentrations in plasmaa following administration of paromomycin alone or WR 279,396 to children on day 1 and day 20
Treatment Parameterb
Value for time point
Day 1 Day 1 (sub 313c) Day 20
0 h 4 h 0 h 4 h 0 h 4 h
Paromomycin No. of subjects 18 18 18 18
Mean concn, ng/ml (% CV) 5.00 (282.9) 143 (98.7) 75.7 (424.3) 693 (424.3)
GeoMean concn 1.73 94.4 51.8 505
WR 279,396 No. of subjects 16 16 15 15 16 16
Mean concn, ng/ml (% CV) 38.9 (386.6) 507 (326.5) 0.0 (0.0) 143 (82.2) 99.0 (133.4) 880 (98.6)
GeoMean concn 1.74 24.4 97.1 13.9 605
P value (WR279,396
vs paromomycin)
0.333 0.999 0.514 0.466
a Plasma concentrations normalized to the average cream dose of 2.81 g.
b GeoMean, geometric mean.
c Data for subject no. 313 were omitted.
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cal administration of paromomycin alone and WR 279,396 were
obtained. Since paromomycin was not given intravenously (i.v.)
or intramuscularly (i.m.) to the study subjects, a paromomycin
total body clearance value from a published report (13) was used
in performing these estimates of the amount of paromomycin
absorbed (Amt abs.) and percent of topical paromomycin dose
absorbed (% dose). There are several assumptions for applying
this estimation method. Since the published article by Kanyok et
al. (13) presented the paromomycin PK after single i.m. dosing, it
must be assumed that the extent of i.m. absorption is 100% in
order to utilize the reported clearance values for the amount and
% dose calculations. Also, it is assumed that on day 20, there is a
steady statewith respect to the paromomycinmultiple-dosing rate
and the resulting plasma concentration profiles.
Table 4 presents individual and summary percentages of the
dose absorbed (% dose) estimates, as well as the accumulation in
AUC/D for day 20 compared to day 1. Values for the % dose
absorbed were highly variable, ranging from 4.15 to 24.9% for the
paromomycin-alone group and 0.0 to 25.9% for the WR 279,396
group. The means SD for the percentage of dose absorbed were
12.0% 6.26% and 9.68% 6.05% for paromomycin alone and
WR 279,396, respectively. Although not statistically evaluated,
there appear to be no differences in the percentage of the topical
dose systemically absorbed between the formulations. Also, there
did not appear to be any trends between study sites. These % dose
absorbed calculations were not performed on day 1 results, since
steady state during day 1 should not be assumed. Based on the
AUC/D accumulation from day 1 to day 20 as shown in Table 4,
systemic steady state is not reached on day 1.
The accumulation in paromomycin concentrations in plasma
on day 20 compared to results on day 1 was evaluated from the
ratio of 24-h AUC values corrected for dose for day 20 divided by
day 1. This accumulation factor could not be calculated for all sub-
jects, since 7 of 26 displayed plasma concentrations below the LLOQ
on day 1 and 1 of 26 did so on day 20. For accumulation factors that
could bedetermined, themean (range)was 6.26 (0.74 to 31.9) for the
paromomycin-alone group and 4.94 (1.39 to 16.0) for the WR
279,396 group.No trendswere apparent between treatments or sites.
Influence of demographic factors, dose, and site on paromo-
mycin PK parameters.The relationships between treatment, sub-
ject, and lesion characteristics (site, age, gender, weight, BSA, cre-
atinine clearance, treatment prescribed, cumulative dose, and
lesion area) and PK outcomes (Cmax, Tmax, AUC, Cmax/dose, and
AUC/dose) were examined by ordinary least-squares regression.
Upon evaluation of day 1 and day 20 results both combined and
separately, none of the characteristics achieved a significance level
of 0.05 or less for any of the PK outcomes. When subgroups of
treatment and site were examined, lesion size affected (P 0.05)
the AUC/dose and % dose absorbed values on day 20 only in the
paromomycin-alone subjects. Figure 3 shows % dose absorbed
versus lesion size on day 20 for both treatments, and the correla-
tion coefficient (r) is 0.334 (P 0.095). Examining this relation-
ship by treatment group showed the % dose absorbed versus le-
sion size relationship to have r values of 0.571 (P  0.042) for
paromomycin-alone and 0.223 (P  0.463) for WR 279,396
creams. Since there were no treatment effects, this treatment-de-
pendent relationship may be a result of a greater lesion size range
in the paromomycin-alone-treated subjects.
DISCUSSION
The objectives of these two studies in Peru and Panama were to
evaluate the PK, safety, and efficacy of WR 279,396 (paromomy-
TABLE 4 Predicted percentages of paromomycin systemic absorption (% dose) following administration of WR 279,396 to adult subjects on day 20
Day, treatment, and statistic Dose (g) CumDosea (g) AUC0–24 (ng · h/ml) AUC/D
b (h/ml) Amt abs.c (mg) % Dose Accumd
Day 1
Paromomycin
No. of subjects 13 13 13 13
Mean value (SD) 2.1 (1.5) 2.1 (1.5) 2,180 (2,621) 823.5 (815.1)
% CV 69.8 69.8 120.2 99.0
GeoMean value 1.7 1.7 278.7 156.0
WR 279,396
No. of subjects 13 13 13 13
Mean value (SD) 2.6 (1.4) 2.6 (1.4) 975.6 (1,078) 344.3 (309.2)
% CV 54.7 54.7 110.5 89.8
GeoMean value 2.3 2.3 125.7 65.69
Day 20
Paromomycin
No. of subjects 13 13 13 13 13 13 10
Mean value (SD) 3.4 (1.7) 53.3 (21.4) 8,575 (7,268) 2,344 (1,249) 65.2 (48.9) 12.0 (6.26) 6.26 (9.34)
% CV 50.4 40.1 84.8 53.3 75.1 52.0 149.2
GeoMean value 3.0 48.6 6,173 2,070 47.2 10.6 3.21
WR 279,396
No. of subjects 13 13 13 13 13 13 9
Mean value (SD) 3.4 (1.9) 57.8 (25.3) 6,037 (3,956) 1,926 (1,466) 46.1 (28.7) 9.68 (6.05) 4.94 (4.40)
% CV 55.4 43.7 65.5 76.1 62.3 62.5 89.1
GeoMean value 2.8 52.1 2,681 1,022 21.2 4.96 3.82
a CumDose, cumulative dose over 20 days.
b AUC/D, AUC0–24 divided by administered dose of cream.
c Amt abs., amount of paromomycin systemically absorbed; based upon an adult paromomycin clearance of 7.32 liters/h/1.73 m2.
d Accum, accumulation: (AUC/D for day 20)/(AUC/D for day 1).
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cin-gentamicin) and paromomycin alone in subjects with uncom-
plicated CL. Both creams contain 15% paromomycin. and WR
279,396 cream also contained 0.5% gentamicin. Extensive blood
sampling could not be conducted in children, limiting the ability
to perform a thorough PK analysis for the pediatric subjects.
Blood was collected in children only prior to dosing and at the
putativeTmax after the first and last days of study drug application.
In addition, precise exposure to the drug was estimated based on
weighing the tubes of cream before and after each day’s applica-
tion, such that cream that adhered to the dressing or finger of the
person applying the cream would result in overestimation of the
amount actually applied to the lesion and available for absorption.
Although the percentage of a topically applied drug dose that
reaches the systemic circulation is generally quite low, the perme-
ability of infected or damaged skin can be considerably greater. In
the treatment of CL lesions, several weeks of topical cream applica-
tion may be required, and thus there is a potential for the systemic
drugaccumulationofagentspresent in the topical cream.ThePKand
systemic exposure of paromomycin and gentamicin resulting from
the application of these two topical creams were evaluated.
Although the PK and safety of parenteral formulations of paro-
momycin and gentamicin separately are well known, it is not
known to what extent these two drugs will be absorbed into the
systemic circulation when applied topically in this investigational
product formulation to an open skin wound, such as a CL lesion.
Studies of paromomycin systemic absorption after topical appli-
cation in mice have shown low absorption (0.5% of dose) across
intact skin but 91.5% across stripped skin (15). Also, gentamicin
topical absorption is low and is reported as2% across the intact
cornea (16). Gentamicin and paromomycin have similar physio-
chemical properties, and, as with paromomycin, damaged skin
may increase the systemic absorption of topical gentamicin (15).
Only 9 collections from more than 300 collections on day 20
had total plasma gentamicin concentration above the LLOQ. For
this reason, no PK analysis was performed with the gentamicin
exposure results. Among these, no pattern was noted between
adults (6/9) and children (3/9). It appears that gentamicin sys-
temic exposure from topical application of WR 279,396 cream to
CL lesions is quite low and clinically insignificant.
Although quite variable, paromomycin systemic exposure fol-
lowing topical administration of both creams was observed, and
PK analysis was performed based upon paromomycin plasma
concentrations. On day 1, the Cmax varied from 0 to 1,100 ng/ml
(mean SD 331 372 ng/ml) for paromomycin alone and 0 to
331 ng/ml (131  112 ng/ml) for WR 279,396. On day 20, paro-
momycin Cmaxs were greater than those on day 1, with ranges of
214 to 2,240 ng/ml (1,000  750 ng/ml) and 0 to 1,840 ng/ml
(660  486 ng/ml) for the two formulations, respectively. The
24-h paromomycin exposure (AUC0–24) on day 20 was 8,575 
7,268 ng/ml for paromomycin alone and 6,037 3,956 ng/ml for
WR 279,396.
Plasma paromomycin concentrations in children were also
quite variable. On day 20, 4-h paromomycin plasma concentra-
tions were 841 794 ng/ml and 881 1,170 ng/ml for paromo-
mycin alone and WR 279,396, respectively. The trough or time
zero plasma concentrations on day 20 were 85.1 52.7 and 100
149 ng/ml for the same. These trough and 4-h paromomycin
plasma concentration are within the range noted for adults.
Using literature that has reported total-body clearances for
paromomycin (13), the amount and percentage of paromomycin
systemically absorbed on day 20 were estimated. For paromomy-
cin alone, the percent dose and amount systemically absorbed
were 12.0% 6.26% (range, 4.15 to 24.9%) and 65.2 48.9 mg
(11.1 to 159 mg). These same estimates for WR 279,396 were
9.68% 6.05% (0 to 25.9%) and 46.1 28.7 mg (0 to 79.6 mg).
If all adults in the study received i.m. doses of 1,000 mg/day (15
mg/kg/day 70 kg), applying the average BSA-adjusted paromo-
mycin clearance, the amount topically absorbed expressed as a
percentage of this standard i.m. dose would be 6.52% 4.89% for
paromomycin alone and 4.61%  2.87% for WR 279,396. Thus,
this would be approximately 5% of a parenteral i.m. dose.
Average paromomycin concentrations in plasma over 24 h on
day 20, calculated as AUC0–24/24 h, were 0.36  0.30 g/ml and
0.25  0.16 g/ml for paromomycin alone and WR 279,396, re-
spectively. In a population PK study performed by the Institute for
One World Health (IOWH), including 448 visceral leishmaniasis
patients treated with 21 days of 15-mg/kg/day i.m. paromomycin,
steady-state peak and trough plasma concentrations were 18.7
9.45 and 1.41 4.32 g/ml in male patients and 17.6 8.07 and
1.11 3.89g/ml in female patients (16). Based upon a single i.m.
dose paromomycin PK study, 15mg/kg/daywould be predicted to
yield average steady-state plasma paromomycin concentrations of
4.35 1.10g/ml (13). This comparison of plasmaparomomycin
concentration results in the current study to results reported or
predicted in these i.m. investigations also suggests that an average
of between 6 and 9% of a standard i.m. dose is being systemically
absorbed after topical application of these creams to lesions.
Themean paromomycin t1/2s for both formulations and for both
day 1 and day 20 ranged from 4.15 to 6.94 h. The apparent terminal
t1/2 could be estimated in 9 of 26 subjects during day 1 and in 17 of 26
subjects on day 20. The fact that the t1/2 following i.m. dosing is re-
ported as 2.64 0.82 h suggested that the apparent t1/2 noted in the
present topical study represents the topical systemic absorption rate,
not the elimination rate (13).This apparent t1/2 didnot appear tovary
between formulations or between study days.
It was possible to evaluate a drug accumulation factor (mea-
sured as the ratio of dose-corrected AUCs for day 20/day 1) for 19
of the 26 subjects. This accumulation factor for AUC or exposure
varied from 0.74 through 31.9, with mean values of 6.26 and 4.94
for paromomycin alone andWR 279,396, respectively. This accu-
mulation is far greater than that expected for a drug with an ap-
parent t1/2 of 2.64 (i.m.) or 4.15 to 6.94 (topical) h. A 7-h t1/2 and
FIG 3 Comparisons of estimated % dose absorbed and AUC/dose versus
lesion size at day 20. Paromomycin-alone cream. Œ; WR 279,396 cream, .
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once-a-day dosing would be expected to lead to only 10% accu-
mulation or a factor of 1.1. It is expected that with continuous
topical application on the same site, skin tissue binding and up-
take may become saturated, with greater portions of the later top-
ical doses being systemically absorbed. This could explainwhy day
20 plasma concentrations are 5 to 6 times that observed for the
first dose, even though paromomycin has a short t1/2 with little
expected accumulation on multiple dosing.
Accumulation of topically applied drugs in the skin has been
described previously (18, 19). For example, Testim (testosterone
gel) is a clear to translucent hydroalcoholic topical gel containing
1% testosterone (Testim prescribing information; Auxilium
Pharmaceuticals, Inc., 2009) that provides continuous transder-
mal delivery of testosterone for 24 h. Approximately 10% of the
applied testosterone dose is absorbed across skin of average per-
meability during a 24-h period. PK studies of this drug suggested
that the skin serves as a reservoir for the sustained release of testo-
sterone into the systemic circulation. Repeated applications of
topical clonidine show increased systemic availability on contin-
ued application (19).
The possible relationships between AUC and Cmaxs with the
doses administered, the treatment, the clinical site, and the sub-
ject’s weight, age, sex, BSA, CrCl, and lesion size were explored.
Only the dose on day 1 was found to have an influence on the
AUC0-24 for the same day. Subject demographic characteristics,
site, and treatment were not found to affect the paromomycin PK
parameters or exposure. This is consistent with a previous popu-
lation study in which age, gender, height, or serum creatinine
values do not alter the paromomycin PK (17).
In summary, the potential systemic absorption and exposure
to paromomycin and gentamicin were investigated following top-
ical administration of the investigational topical treatments paro-
momycin-alone cream and WR 279,396. In the case of gentami-
cin, no clinically significant systemic absorption with respect to
levels associated with aminoglycoside toxicity appeared to occur
in adults or children. On day 20, for WR 279,396 cream, the per-
cent dose and amount of paromomycin systemically absorbed
were estimated to be 9.68% 6.05% (0 to 25.9%) and 46.1 28.7
mg (0 to 79.6 mg). This was similar to findings for the paromo-
mycin-alone cream. This degree of absorption represents approx-
imate 5 to 9% of the exposure that is expected from standard paro-
momycin i.m. therapy. Paromomycin exposure following topical
administration on day 20 was 5 to 6 times greater than that on day 1
and was probably a result of increased systemic absorption during
multiple dosing due to drug saturation of skin tissue. No demo-
graphic factors, such as age, gender, weight, CrCL, or lesion size, ap-
peared to influence the observed systemic absorption parameters. As
expected for measurements of systemic absorption following topical
administration, PK parameters were highly variable and may reflect
the degree of tissue damage and drug dose, which was a function of
lesion size. Based upon recent clinical trials, topical treatment with
this cream appears to have efficacy and safety benefits with little con-
cern of systemic drug toxicity.
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